Halozyme Therapeutics | HALO - 销售和管理费用



金融业
股票价格
USD
资产
USD 2.58B
现金及等价物
USD 163.14M
销售成本
USD 108.68M
流动资产
USD 933.02M
流动负债
USD 344.44M
债务
USD 2.14B
EBIT
USD -63.72M
EBITDA
USD 328.81M
员工
350
EPS每股收益
USD 2.28
股本和储备
USD 143.54M
销售毛利
USD 297.47M
债务利息支出
USD 5.59M
贷款资金
USD 1.94B
市值
USD 13.18B
净收入
USD 229.91M
营业费用
USD 193.35M
营业利润
USD -63.72M
普通股股本
USD 114.04M
PE价格收益
12.51
税前利润
USD 180.33M
销售收入
USD 481M
销售和管理费用
USD 57M
股票
USD 137.14M
贸易债权人
USD 23.61M
应收帐款人
USD 453.33M


销售和管理费用 更改 日
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.72B 134M 2026-06
Baxter International USD 735M 7M 2026-06
Cara Therapeutics USD 2.09M 96K 2026-03
Cytokinetics USD 104.4M 499K 2026-06
DBV Technologies USD 13.4M 8.14M 2026-03
Eli Lilly USD 3.43B 496M 2026-06
Halozyme Therapeutics USD 57M 10.71M 2026-06
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
MannKind USD 58.3M 4.22M 2026-06
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Pfizer USD 3.41B 496M 2026-06
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
United Therapeutics USD 206.7M 50.1M 2026-06
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12